Site in Medical Technology

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... percent of SIMPONI treated patients had injection site reactions compared with 2.2 percent in control-treated patients. The majority of the injection site reactions were mild and moderate, and the most frequent manifestation was injection site erythema. For the Full U.S. ...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

... percent and 1 percent of patients, and injection site reactions (ISR) through week 16 occurred in 3 ... nausea, abnormal liver tests, redness at site of injection, high blood pressure, bronchitis, ... company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com . ...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

... experiencing serious adverse events. Injection site reactions occurred in eight percent of patients ... experiencing serious adverse events. Injection site reactions occurred in 11 percent of patients ... nausea, abnormal liver tests, redness at site of injection, high blood pressure, bronchitis, ...

FDA Approves Vanda Pharmaceuticals' Fanapt(TM) for the Treatment of Schizophrenia

... Relations tab and are advised to go to the Web site at least 15 minutes early to register, download, ... The call will also be archived on the Vanda Web site for a period of 30 days, through June 6, 2009. ... are available free of charge at the SEC's web site at www.sec.gov or from Vanda at ...

Transcept Pharmaceuticals to Report First Quarter 2009 Results

... from the Investors section on the corporate web site at www.transcept.com . A webcast replay can be accessed on the corporate web site beginning May 13, 2009 at the same time as the conference call and will remain on the site through May 27, 2009. About Transcept ...

Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy

... during degarelix therapy included injection site reactions (e.g. pain, erythema, swelling or ... Specifically relating to the injection site adverse reactions, most were transient, of mild ... (<1%). Grade 3 (severe) injection site reactions occurred in two percent or less of ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... PEGINTRON or PEGINTRON/REBETOL are injection site inflammation/reaction, fatigue/asthenia, ... neutropenia, fatigue, anorexia, injection site erythema and vomiting. In a study with ... was a 23-24% incidence overall for injection site reactions or inflammation. Individual ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... PEGINTRON or PEGINTRON/REBETOL are injection site inflammation/reaction, fatigue/asthenia, ... neutropenia, fatigue, anorexia, injection site erythema and vomiting. In a study with ... was a 23-24% incidence overall for injection site reactions or inflammation. Individual ...

Innocoll Announces Dosing of Last Patient in Second US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Colorectal Surgery Patients

... SURGICAL IMPLANT for the prevention of surgical site infections. The trial is being conducted at ... considered to be the most prone to surgical site infection (SSI). Patients in the treatment group ... demonstrated a 70 percent decrease in surgical site infections from 18.4 percent in the control group ...

Innocoll Announces Dosing of Last Patient in US Phase 3 Clinical Trial to Investigate GENTAMICIN SURGICAL IMPLANT for Prevention of Surgical Site Infections in Cardiac Surgery Patients

... SURGICAL IMPLANT for the prevention of surgical site infections. The trial is being conducted at ... tissue infections and the prevention of surgical site infections in both hard and soft tissues. ... trials in the U.S. for the prevention of surgical site infections and has received FDA fast-track ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... PEGINTRON or PEGINTRON/REBETOL are injection site inflammation/reaction, fatigue/asthenia, ... neutropenia, fatigue, anorexia, injection site erythema and vomiting. In a study with ... was a 23-24% incidence overall for injection site reactions or inflammation. Individual ...

Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment

... private databases, CPR analyzes each investigator site for multiple criteria to identify the optimal ... database, provides a powerful dataset for site selection and patient recruitment. "The clinical trials industry has repeatedly identified site initiation as a primary cause of delays," ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. ... in severity as treatment continues. Application site disorders were common (47%), but all were mild ... no patient discontinued, and included injection site inflammation and reaction (i.e., bruise, ...

Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated

... how it can be prevented through vaccination. The site offers reporters, consumers and health-care ... service. By typing in their 5-digit zip code, site visitors can receive a list of immunization clinics in their area. site visitors may also schedule reminders and sign up ...

Colesevelam HCl Lowered LDL Cholesterol in Pediatric Patients With Heterozygous Familial Hypercholesterolemia

... (877-431-7763), or go to the Welchol web site at http://www.Welchol.com . About Daiichi ... s-treatment-familial-hypercholesterolemia.htm. site accessed September 19, 2008. (2) ... s-treatment-familial-hypercholesterolemia.htm. site accessed September 19, 2008. (4) American ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. ... in severity as treatment continues. Application site disorders were common (47%), but all were ... (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving ...

NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy

... they cannot penetrate the nail and access the site of infection. The results were reported this ... dermis to more than 1 centimeter away from the site of application," said Susan Ciotti, Ph.D., ... because they are unable to penetrate to the site of infection. "The safe and efficient delivery ...

ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver

... - Multi-Center Study in Skin Graft Donor site Patients - ADDISON, Texas, Oct. 21 ... patients being enrolled. The first study site has been initiated and the Company plans to ... with Altrazeal(TM) Silver being applied to one site and the competitive dressing being applied to the ...

Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children

... improves their health and well-being. A new Web site from the National Institutes of Health (NIH), ... to enroll their child in a study." The Web site describes why research in children is important, ... and other conditions -- developed the Web site in collaboration with New England ...

deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders

... of these molecules in the PDE4 enzymatic active site competitively with cAMP. As cAMP is of ... deCODE chemistry team to identify a novel binding site for allosteric modulators in the PDE4 regulatory domain. Binding of an allosteric modulator at that site is non-competitive with cAMP. DG071 has been ...

F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy

... adverse reaction was constipation. Application site reactions were reported but were mild and did not ... by the underlying condition. Mild application site reactions have occurred; remove patch if severe ... should avoid direct exposure of application site to natural or artificial sunlight by covering ...

Novare Announces Successful Series of Single Port Lap Band Procedures With RealHand(R) High Dexterity Instruments

... upper abdominal trocar placement that is often a site for significant patient discomfort. "This is a ... said Dr. Teixeira. "By reducing the operative site to one single incision in the belly button we are ... For more information, visit the company's web site at http://www.novaresurgical.com . ...

Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain

... to provide pain control directly at the surgical site and thus reduce the level of additional ... to provide continuous, long-term analgesia at the site of a surgical wound. Innocoll has already ... in post-operative pain, prevention of surgical site infection, and treatment of diabetic ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. ... in severity as treatment continues. Application site disorders were common (47%), but all were ... (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving ...

FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors

... in the U.S. may have a tumor for which the site of origin is uncertain after the initial ... better decisions. "Knowing the primary tumor site with greater certainty enables more appropriate ... identification of the primary tumor site or tissue of origin. Targeting therapy to ...

Data Presented at American Headache Society's Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics' Tezampanel

... adverse events compared to placebo were injection site pain (5.1 percent vs. 20 percent), injection site burning (3.8 percent vs. 6.7 percent), dizziness ... indicated above, the reported rates of "injection site ...

TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate

... By acting at both the AMPA and kainate receptor site to competitively block the binding of glutamate, ... on the home page of TorreyPines Therapeutics' Web site at http://www.torreypinestherapeutics.com . ... available on TorreyPines Therapeutics' Web site until July 25. About TorreyPines Therapeutics ...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

... swelling, bruising and pruritis at the injection site and transient lymph node swelling and pain. In ... be simultaneously web cast on Auxilium's web site and archived for future review until July 3, ... tab on the home page of the Company's web site at http://www . auxilium.com Web cast: ...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

... of 40 ng/kg/min, infrequent subcutaneous catheter site changes, and proactive pain management. ... administration of Remodulin (e.g., infusion site pain), they tolerate treatment very well and ... of infusion. For subcutaneous infusion, infusion site pain and infusion site reaction (redness and ...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

... adverse reactions vs. placebo were injection site reactions (20 percent vs. 14 percent), upper ... (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 ... Medication Guide, is available on the Web site http://www.humira.com or in the United States ...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

... however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. ... in severity as treatment continues. Application site disorders were common (47%), but all were ... (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving ...

Amikacin Inhale Shows Promising Results in Phase II Study

... shows that targeting antibiotic therapy to the site of infection might offer superior bacterial ... delivers the antibiotic directly to the site of infection, without reaching high systemic ... Inhale, which fights pneumonia directly at the site of infection, may be able to help decrease ...

ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study

... reduction in general disorders and administration site conditions when compared to Navelbine(R) ... entitled "Tolerability and incidence of infusion site reactions with emulsion formulation of ... of ADVENTRX. "The improvement in injection site reactions could translate into a real benefit ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

... however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. ... in severity as treatment continues. Application site disorders were common (47%), but all were ... (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving ...

Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations

... call 877-4-DSPROD (877-437-7763) or go to the web site http://www.azor.com . About Daiichi Sankyo, ... (5) http://www.cdc.gov/nchs/nhanes.htm site accessed 5/14/2008 (6) Chobanian, A.V., et al. ... site accessed 5/17/2007 (8) ...

New Data Shows 45 Percent of Patients with Stage 1 Hypertension Reached Normotension with BENICAR(R) and BENICAR HCT(R)

... site accessed 4/18/2008 3. Kearney, P. et al. ... site accessed 4/18/2008 5. http://www.americanheart.org/presenter.jhtml?identifier=4621 site accessed 4/18/2008 ...

Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests

... learn more about our organization, visit our Web site at: http://www.labcorp.com . (1) American Heart Association (AHA) 2008. Web site accessed Febuary 15, 2008: ... (2) World Health Organization (WHO) 2008. Web site accessed Feburary 15, 2008: ...

Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine

... TPM to deliver lidocaine (5%) to a targeted local site after a single topical application, while ... concentrations were measured in the skin at the site of application, as well as in the underlying ... concentrations were measured in the skin at the site of application, as well as in the underlying ...

Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections

... infections and the prevention of surgical site infections in both hard and soft tissues; and is ... in the US for the prevention of surgical site infections. The development of the topical ... for the treatment and prevention of surgical site infections, is approved for sale in 49 countries ...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

... however, the incidence of some (e.g., injection site reactions, fever, rigors, nausea) were higher. ... in severity as treatment continues. Application site disorders were common (47%), but all were ... (i.e., bruise, itchiness, irritation). Injection site pain was reported in 2% of patients receiving ...